Candel Therapeutics, Inc.
CADL
$4.76
$0.224.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -30.60% | 139.26% | -16.56% | -31.85% | 366.17% |
| Gross Profit | 30.60% | -139.26% | 16.56% | 31.85% | -369.15% |
| SG&A Expenses | 2.48% | 10.60% | -1.22% | -8.71% | -2.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.46% | -1.17% | -10.52% | -17.97% | 22.09% |
| Operating Income | 25.46% | 1.17% | 10.52% | 17.97% | -22.55% |
| Income Before Tax | -26.84% | -26.21% | -131.30% | 6.53% | -118.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.84% | -26.21% | -131.30% | 6.53% | -118.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.84% | -26.21% | -131.30% | 6.53% | -118.28% |
| EBIT | 25.46% | 1.17% | 10.52% | 17.97% | -22.55% |
| EBITDA | 26.08% | 1.21% | 10.93% | 18.63% | -22.83% |
| EPS Basic | -3.37% | -13.99% | -123.92% | 7.40% | -117.62% |
| Normalized Basic EPS | -1.47% | -13.99% | -123.87% | 7.42% | -110.10% |
| EPS Diluted | -3.37% | -13.99% | -123.92% | 7.40% | -117.62% |
| Normalized Diluted EPS | -1.47% | -13.99% | -123.87% | 7.42% | -110.10% |
| Average Basic Shares Outstanding | 22.71% | 10.70% | 3.31% | 0.96% | 0.28% |
| Average Diluted Shares Outstanding | 22.71% | 10.70% | 3.31% | 0.96% | 0.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |